Multiplex analysis of anti-apoptotic BCL2 family and caspase 3 activation by microbead arrays

Assay and Drug Development Technologies

Volumn 12, Issue 3, 2014, Pages 190-196

  Lam, Lloyd T ^a   Roberts Rapp, Lisa ^a  

^a ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; FLAVOPIRIDOL; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NAVITOCLAX; PF 562271; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; MICROSPHERE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL LYSATE; CELL VIABILITY ASSAY; CYTOLYSIS; ENZYME ACTIVATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MICROBEAD ARRAY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; GENE EXPRESSION PROFILING; LUMINESCENCE; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROCEDURES; PROTEIN ANALYSIS; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMANS; LUMINESCENT MEASUREMENTS; MICROSPHERES; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84898847538     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.557     Document Type: Article

References (20)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
2. Cory S, Huang DC, Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-8607. (Pubitemid 38028528)
3. Tse C, Shoemaker AR, Adickes J, et al.: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
4. Tahir SK, Yang X, Anderson MG, et al.: Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-1183.
5. van Delft MF, Wei AH, Mason KD, et al.: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-399. (Pubitemid 44711953)
6. Lin X, Morgan-Lappe S, Huang X, et al.: 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl- XL inhibitor ABT-737. Oncogene 2007;26:3972-3979. (Pubitemid 46884293)
7. Lestini BJ, Goldsmith KC, Fluchel MN, et al.: Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009;8:1587-1595.
8. Lam LT, Lu X, Zhang H, Lesniewski R, Rosenberg S, Semizarov D: A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Mol Cancer Ther 2010;9:2943-2950.
9. Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 2009;4:e6651.
10. Hauck P, Chao BH, Litz J, Krystal GW: Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 2009;8:883-892.
11. Chen S, Dai Y, Harada H, Dent P, Grant S: Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-791. (Pubitemid 46192219)
12. Lam LT, Zhang H, Chyla B: Biomarkers of therapeutic response to BCL2 antagonists in cancer. Mol Diagn Ther 2012;16:347-356.
13. Chen J, Jin S, Abraham V, et al.: The Bcl-2/Bcl-XL/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 2011;10:2340-2349.
14. Bodet L, Gomez-Bougie P, Touzeau C, et al.: ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011;118:3901-3910.
15. Touzeau C, Dousset C, Bodet L, et al.: ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res 2011;17:5973-5981.
16. Zhang H, Guttikonda S, Roberts L, et al.: Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2011;30:1963-1968.
17. Lam LT, Pickeral OK, Peng AC, et al.: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:RESEARCH0041.
18. Chao SH, Fujinaga K, Marion JE, et al.: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-28348.
19. Hao H, Naomoto Y, Bao X, et al.: Focal adhesion kinase as potential target for cancer therapy (Review). Oncol Rep 2009;22:973-979.
20. Roberts WG, Ung E, Whalen P, et al.: Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008;68: 1935-1944. (Pubitemid 351416580)